243 related articles for article (PubMed ID: 11075414)
1. Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000.
Sudre P; Rickenbach M; Taffé P; Janin P; Volkart AC; Francioli P;
Schweiz Med Wochenschr; 2000 Oct; 130(41):1493-500. PubMed ID: 11075414
[TBL] [Abstract][Full Text] [Related]
2. [The Swiss HIV Cohort Study--a link between clinical research and medical practice].
Opravil M; Rickenbach M; Ledergerber B
Ther Umsch; 1998 May; 55(5):329-34. PubMed ID: 9643131
[TBL] [Abstract][Full Text] [Related]
3. [Cause of death and autopsy findings in patients of the Swiss HIV Cohort Study (SHCS)].
Semela D; Glatz M; Hunziker D; Schmid U; Vernazza PL
Schweiz Med Wochenschr; 2000 Nov; 130(45):1726-33. PubMed ID: 11109604
[TBL] [Abstract][Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
6. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
7. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
Polesel J; Clifford GM; Rickenbach M; Dal Maso L; Battegay M; Bouchardy C; Furrer H; Hasse B; Levi F; Probst-Hensch NM; Schmid P; Franceschi S;
AIDS; 2008 Jan; 22(2):301-6. PubMed ID: 18097233
[TBL] [Abstract][Full Text] [Related]
8. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
9. [Sex differences in disease course: analysis of the Swiss HIV cohort study].
Schmid M; Twisselmann W; Jacquat BJ; Ledergerber B; Battegay M; Egger M
Schweiz Med Wochenschr; 1996 Dec; 126(51-52):2234-6. PubMed ID: 9011933
[TBL] [Abstract][Full Text] [Related]
10. Outline of the Human Retrovirus Registry: profile of a Puerto Rican HIV infected population.
Gómez MA; Velázquez M; Hunter RF
Bol Asoc Med P R; 1997; 89(7-9):111-6. PubMed ID: 9419928
[TBL] [Abstract][Full Text] [Related]
11. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
12. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
13. A large French prospective cohort of HIV-infected patients: the Nadis Cohort.
Pugliese P; Cuzin L; Cabié A; Poizot-Martin I; Allavena C; Duvivier C; El Guedj M; de la Tribonnière X; Valantin MA; Dellamonica P;
HIV Med; 2009 Sep; 10(8):504-11. PubMed ID: 19486189
[TBL] [Abstract][Full Text] [Related]
14. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
15. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
16. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
Seminari E; De Silvestri A; Boschi A; Tinelli C
AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
[TBL] [Abstract][Full Text] [Related]
17. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
[TBL] [Abstract][Full Text] [Related]
18. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.
Nesheim SR; Kapogiannis BG; Soe MM; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
Pediatrics; 2007 Jul; 120(1):100-9. PubMed ID: 17606567
[TBL] [Abstract][Full Text] [Related]
19. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics.
Ledergerber B; von Overbeck J; Egger M; Lüthy R
Soz Praventivmed; 1994; 39(6):387-94. PubMed ID: 7817627
[TBL] [Abstract][Full Text] [Related]
20. Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis.
Bogaards JA; Weverling GJ; Geskus RB; Miedema F; Lange JM; Bossuyt PM; Goudsmit J
Antivir Ther; 2003 Feb; 8(1):43-50. PubMed ID: 12713063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
